Cargando…

Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer

A natural bioactive compound named calotropone has been reported as a drug candidate for several cancers, including pancreatic cancers. Herein, we used molecular docking approach to test the possible mechanisms of action of calotropone in inhibiting the growth of pancreatic cell cancer with gemcitab...

Descripción completa

Detalles Bibliográficos
Autores principales: Purnama, Agnia, Rizki, Diva Rayyan, Qanita, Intan, Iqhrammullah, Muhammad, Ahmad, Khairunnas, Mardina, Vivi, Puspita, Kana, Hasballah, Kartini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820343/
https://www.ncbi.nlm.nih.gov/pubmed/35223440
http://dx.doi.org/10.4103/japtr.japtr_143_21
_version_ 1784646206891229184
author Purnama, Agnia
Rizki, Diva Rayyan
Qanita, Intan
Iqhrammullah, Muhammad
Ahmad, Khairunnas
Mardina, Vivi
Puspita, Kana
Hasballah, Kartini
author_facet Purnama, Agnia
Rizki, Diva Rayyan
Qanita, Intan
Iqhrammullah, Muhammad
Ahmad, Khairunnas
Mardina, Vivi
Puspita, Kana
Hasballah, Kartini
author_sort Purnama, Agnia
collection PubMed
description A natural bioactive compound named calotropone has been reported as a drug candidate for several cancers, including pancreatic cancers. Herein, we used molecular docking approach to test the possible mechanisms of action of calotropone in inhibiting the growth of pancreatic cell cancer with gemcitabine as the positive control. By employing AutoDock Vina, we studied the molecular interaction between calotropone and pancreatic cancer-associated proteins, namely Glucosaminyl (N-Acetyl) Transferase 3, Glutamic-Oxaloacetic Transaminase 1, Tyrosine-protein kinase Met (c-Met), peroxisome proliferator-activated receptor γ, Budding Uninhibited by Benzimidazole 1, A Disintegrin and Metalloproteinase 10, Sex-determining region Y and Nuclear Factor kappa Beta (Nf-Kβ). Higher affinity energies of calotropone toward the aforementioned proteins (ranging from ‒7.3 to ‒9.3 kcal/mol) indicate that calotropone may work in the same manner as anticancer drug gemcitabine. Highest docking score was found at the interaction of calotropone and Nf-Kβ (‒9.3 kcal/mol).
format Online
Article
Text
id pubmed-8820343
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-88203432022-02-24 Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer Purnama, Agnia Rizki, Diva Rayyan Qanita, Intan Iqhrammullah, Muhammad Ahmad, Khairunnas Mardina, Vivi Puspita, Kana Hasballah, Kartini J Adv Pharm Technol Res Original Article A natural bioactive compound named calotropone has been reported as a drug candidate for several cancers, including pancreatic cancers. Herein, we used molecular docking approach to test the possible mechanisms of action of calotropone in inhibiting the growth of pancreatic cell cancer with gemcitabine as the positive control. By employing AutoDock Vina, we studied the molecular interaction between calotropone and pancreatic cancer-associated proteins, namely Glucosaminyl (N-Acetyl) Transferase 3, Glutamic-Oxaloacetic Transaminase 1, Tyrosine-protein kinase Met (c-Met), peroxisome proliferator-activated receptor γ, Budding Uninhibited by Benzimidazole 1, A Disintegrin and Metalloproteinase 10, Sex-determining region Y and Nuclear Factor kappa Beta (Nf-Kβ). Higher affinity energies of calotropone toward the aforementioned proteins (ranging from ‒7.3 to ‒9.3 kcal/mol) indicate that calotropone may work in the same manner as anticancer drug gemcitabine. Highest docking score was found at the interaction of calotropone and Nf-Kβ (‒9.3 kcal/mol). Wolters Kluwer - Medknow 2022 2022-01-21 /pmc/articles/PMC8820343/ /pubmed/35223440 http://dx.doi.org/10.4103/japtr.japtr_143_21 Text en Copyright: © 2022 Journal of Advanced Pharmaceutical Technology & Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Purnama, Agnia
Rizki, Diva Rayyan
Qanita, Intan
Iqhrammullah, Muhammad
Ahmad, Khairunnas
Mardina, Vivi
Puspita, Kana
Hasballah, Kartini
Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer
title Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer
title_full Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer
title_fullStr Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer
title_full_unstemmed Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer
title_short Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer
title_sort molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820343/
https://www.ncbi.nlm.nih.gov/pubmed/35223440
http://dx.doi.org/10.4103/japtr.japtr_143_21
work_keys_str_mv AT purnamaagnia moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer
AT rizkidivarayyan moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer
AT qanitaintan moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer
AT iqhrammullahmuhammad moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer
AT ahmadkhairunnas moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer
AT mardinavivi moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer
AT puspitakana moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer
AT hasballahkartini moleculardockinginvestigationofcalotroponeasapotentialnaturaltherapeuticagentagainstpancreaticcancer